Here, we present a case of a complete metabolic and serologic remission in a patient with dMMR/MSI-H mCRC and Lynch syndrome-associated prostate cancer under treatment with combined anti-PD-1 and anti-CTLA-4 blockade with nivolumab and ipilimumab after progression under pembrolizumab monotherapy. The gene discussed is PDCD1; the disease is Lynch syndrome.